Title: Centre for NanoHealth Future Healthcare
1Centre for NanoHealthFuture Healthcare
- Dr Steve Conlan
- Director - Centre for NanoHealth
- Institute of Life Science
- School of Medicine
2Overview
- Nanotechnology
- NanoHealth
- Impact of NanoHealth
- Centre for NanoHealth
- Challenges and Opportunities
- RD
3Please turn off your Nanotechnology based
devices.
4The nano-scale
5What is NanoHealth?
6Nanotechnology
- Ability to manipulate and control the properties
and interaction of material where at least 1-D is
nm. - Structural
- Mechanical
- Electronic
- Optical
- Chemical
- Biological
- Computational
- Modelling
Multidisciplinary
For Healthcare
7The impact of NanoHealth
8NanoHealth
has the potential to impact on the prevention,
early and reliable diagnosis and treatment of
diseases.
European Technology Platform on NanoMedicine
Vision Paper (2005)
- NanoHealth embraces five main sub-disciplines
- that in many ways are overlapping
- Analytical Tools
- Imaging Tools
- Materials and Devices
- Novel Therapeutics and Drug Delivery Systems
Nanomedicines - Clinical, Regulatory and Toxicological Issues
ESF forward look on Nanomedicine (2005)
9Impact on Healthcare
- Diagnosing and treating diseases
- Enhancing early intervention
- Non-hospital environments
- Personalised Medicine
10Economic Impact
11Economic Impact
12Global Networks/Global Investment EU, US, South
America and Asia
Alliance for Nanohealth
ETP for Nanomedicine
13Centre for NanoHealth
14Partnership for Success
- Institute of Life Science
- 52m collaborative venture between IBM, Swansea
University, WAG, opening its doors in 2007 -
- Home in the Medical School, 25 specialist teams
(27 Professors and 220 Research active staff)
Multidisciplinary Nanotechnology Centre More
than 5M funding in 2002 from HEFCW, Royal
Society/ Wolfson Foundation, SRIF and Swansea
University Home in Engineering, major research
centre (20 academic staff, 20 RAs and 40 PhD
students)
Outstanding RAE 2008 results (THES) MNC 5th out
of 52 in UK in General Engineering, 80 of
activity rated 4 and 3 ILS 7th out of 70 in UK
in Allied and Professional Health, 55 of
activity 4 and 3
15Partnership for Success
- Successfully managed HEFCW project
- Model interdisciplinary centre
- Self-sustaining (2M per year)
- Strong links with business/IP
- Pan-Wales focus for nanotech
- Successfully managed Objective 1 project
- On time - On budget
- Outputs met sustainability/job creation/strong
links with business/IP - Blue C IBM partnership
- Interdisciplinary research base
- University NHS Trust
- Patient base of 600,000
- Partnership with ILS and MNC
- Joint MNC and ILS laboratories in Morriston
Hospital - Commitment to CNH
16Centre for NanoHealth
- 22M EU Convergence funded project, started
January 2009 - 12 new staff (8 academic, 4 project management
and delivery). - 13M investment in state of the art open access
nano- and bio-facilities. - Industry to come and work with us, access to
facilities, expertise and incubation space.
17Centre for NanoHealth
18Project Funding
- 22 Million, 5 year Knowledge Economy project
- Supported by
- WEFO 10.5 Million
- DHSS 1.5 Million
- Swansea University 7.6 Million
- Industry 2.5 Million
19CNH Targets Deliverables
- Establishing a European RD Centre of Excellence
- Assisting 400 Enterprises (gt80 Welsh SMEs)
- Assisting 100 Individuals
- Creating 450 Jobs
- Achieving sustainability by 2014
- Through Welsh, UK, Industrial and EU funding
20CNH
Building opens Q3 2011 Facilities available now
- Bio-suite
- NanoToxicology
- Cell Imaging
- Tissue Engineering
- Molecular biology
- Microbiology
- Nano-suite
- Class 100/1000 dirty clean room
- Bio-clean room
- Nanostructure growth
- SEM AFM/SNOM
- NMR Rheology
- Printing and Coating
Direct access to Clinical Trials Unit Patient
imaging (MRICT)
21Projects challenges opportunities
22Challenges Opportunities
- Company recruitment
- Business development
- IP
- State Aid
- Managing stakeholder expectations
- Sustainability
23Company recruitment Business development
- Project must offer real opportunities to
businesses across Wales - Take the project to the companies
- Launch Events/BioWales/KTNs etc
- Initial assistance is only the first step in the
relationship - Ensure multiple entries for engagement
- Pool of relevant expertise is essential
- Awareness of funding opportunities is essential
- Beware of ERDF overload internal/institutional
management vital
24CNH
- Access Clinical/Biomedical/Engineering teams
- Fully integrated work flow
- Access at any stage
- Translational applications
- Great opportunities in a new area of healthcare
25IP / IPR
- IP policy of University has to be flexible
- Case by case consideration one model DOES NOT
fit all - Primary consideration to companies SHOW
STOPPER - Has to be managed differently to IP generated in
house - Early negotiation
- Companies understand and appreciate position of
University - State Aid compliance
26State Aid
- Necessarily a major consideration under European
law - Documentation from WEFO offers clarity in their
expectations - Seek legal advice on wording used in business
plans - De minimus scheme easy to implement
27Sustainability RD pipeline
- Start early
- Awareness of all opportunities
- Development pipeline
28Delivery Team work!!
- Medicine
- Engineering
- Finance
- Research and Innovation
- Procurement
- VCs office
- ABMUHB
- External project managers / build team
- WEFO
Early/Continued/Agreed/Managed engagement
29CNH operational structure
30NanoHealth RD
31(No Transcript)
32Diagnostics Biosensors
Novel Materials
Electrode
Antigen
Antibody
Nanowire
Ultra-sensitive biosensor for the detection of
bio-markers using bio-compatible ZnO nanowires.
ZnO nanowires (AFM)
33Cellular Analysis for Clinical Diagnostics
- Surface topography.
- Material properties.
- Spatial resolution 5 - 20 nm.
34Biosensors / Biomarker Detection
- Volume additive printing for the integration of
biosensors with flexible polymer electronics,
photonics and displays.
35Centre for NanoHealth
36Centre for NanoHealth